The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

Jul. 30, 2019
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Judith A. Shizuru, Palo Alto, CA (US);

Irving L. Weissman, Stanford, CA (US);

Kipp Andrew Weiskopf, Sudbury, MA (US);

Aaron Michael Ring, New Haven, CT (US);

Akanksha Chhabra, San Francisco, CA (US);

Peter Schnorr, Sudbury, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 38/1709 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2803 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.


Find Patent Forward Citations

Loading…